Predict your next investment

Corporation
biogaran.fr

See what CB Insights has to offer

About Biogaran

Biogaran is a French pharmaceutical firm, offering a range of bioequivalent medicines.

Biogaran Headquarter Location

France

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Biogaran News

Recruitment of participants for ivermectin trials starts in November — DOST exec

Oct 23, 2021

INQUIRER.net / 02:46 PM October 23, 2021 FILE PHOTO: A box of the drug Ivermectin, made by Biogaran, is pictured on the counter of a pharmacy, as the spread of the coronavirus disease (COVID-19) continues, in Paris, France, April 28, 2020. REUTERS/Benoit Tessier MANILA, Philippines — The recruitment of participants for the clinical trials on the use of ivermectin as COVID-19 treatment will start in November and the initial results may be out by the end of December, an official of the Department of Science and Technology (DOST) said Saturday. According to DOST Undersecretary for Research and Development Rowena Cristina Guevara, pre-clinical trial activities for the ivermectin study are already ongoing. ADVERTISEMENT She said the identified study sites are the Ateneo Quarantine Facility, La Salle Quarantine Facility, University of the Philippines Diliman, and the Makati Science High School Quarantine Facility. “Posible din na magrecruit tayo sa Region 2 at 11 kapag kinulang. Ang ating patient recruitment ay mag-uumpisa ngayong Nobyembre at ang release ng preliminary results ay sa end ng December 2021,” she said at the Laging Handa public briefing. FEATURED STORIES (We may recruit additional participants in Region 2 and 11. Patient recruitment will start this November and the release of preliminary results will be by the end of December.) Guevara noted that the UP Manila College of Pharmacy is formulating the ivermectin capsules to be used in the clinical trials. She said the study will assess the efficacy, safety, and effect on the viral clearance of ivermectin to asymptomatic and non-severe COVID-19 patients in the said isolation facilities. The government has allocated P22 million for the conduct of the study. At present, ivermectin is only approved for human use as an anti-nematode drug. Health authorities have stressed that there is still no evidence that ivermectin can be a treatment for COVID-19. /MUF Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use andacknowledge that I have read the Privacy Policy . For more news about the novel coronavirus click here. For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150. The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link . Read Next

Biogaran Acquisitions

1 Acquisition

Biogaran acquired 1 company. Their latest acquisition was Swipha on March 28, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/28/2017

$99M

Acquired

1

Date

3/28/2017

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.